NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it is planning to sell $450 million of its common stock in a public offering.
The company said that it intends to use the proceeds of the offering for general corporate purposes including the continued advancement of its pipeline of RNAi therapeutics, as well as for working capital and general and administrative expenses.
All of the shares in the offering are being sold by Alnylam.